Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis

Basit Öğe Kaydı
dc.authoridHossein Lanjanian / 0000-0003-4284-6592en_US
dc.authoridFarzad Kiani / 0000-0002-0354-9344en_US
dc.authorscopusidHossein Lanjanian / 57193408899
dc.authorscopusidFarzad Kiani / 36662461100
dc.authorwosidHossein Lanjanian / AAT-7873-2021en_US
dc.authorwosidFarzad Kiani / O-3363-2013en_US
dc.contributor.authorMotieGhader, Habib
dc.contributor.authorTabrizi-Nezhadi, Parinaz
dc.contributor.authorAbad Paskeh, Mahshid Deldar
dc.contributor.authorBaradaran, Behzad
dc.contributor.authorMokhtarzadeh, Ahad
dc.contributor.authorHashemi, Mehrdad
dc.contributor.authorLanjanian, Hossein
dc.contributor.authorJazayeri, Seyed Mehdi
dc.contributor.authorMaleki, Masoud
dc.contributor.authorKhodadadi, Ehsan
dc.contributor.authorNematzadeh, Sajjad
dc.contributor.authorMaghsoudloo, Mazaher
dc.contributor.authorMasoudi-Nejad, Ali
dc.contributor.authorKiani, Farzad
dc.date.accessioned2022-06-16T12:09:50Z
dc.date.available2022-06-16T12:09:50Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.description.abstractLung cancer is the most common cancer in men and women. This cancer is divided into two main types, namely non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Around 85 to 90 percent of lung cancers are NSCLC. Repositioning potent candidate drugs in NSCLC treatment is one of the important topics in cancer studies. Drug repositioning (DR) or drug repurposing is a method for identifying new therapeutic uses of existing drugs. The current study applies a computational drug repositioning method to identify candidate drugs to treat NSCLC patients. To this end, at frst, the transcriptomics profle of NSCLC and healthy (control) samples was obtained from the GEO database with the accession number GSE21933. Then, the gene co-expression network was reconstructed for NSCLC samples using the WGCNA, and two signifcant purple and magenta gene modules were extracted. Next, a list of transcription factor genes that regulate purple and magenta modules’ genes was extracted from the TRRUST V2.0 online database, and the TF–TG (transcription factors–target genes) network was drawn. Afterward, a list of drugs targeting TF–TG genes was obtained from the DGIdb V4.0 database, and two drug–gene interaction networks, including drug-TG and drug-TF, were drawn. After analyzing gene co-expression TF–TG, and drug–gene interaction networks, 16 drugs were selected as potent candidates for NSCLC treatment. Out of 16 selected drugs, nine drugs, namely Methotrexate, Olanzapine, Haloperidol, Fluorouracil, Nifedipine, Paclitaxel, Verapamil, Dexamethasone, and Docetaxel, were chosen from the drug-TG sub-network. In addition, nine drugs, including Cisplatin, Daunorubicin, Dexamethasone, Methotrexate, Hydrocortisone, Doxorubicin, Azacitidine, Vorinostat, and Doxorubicin Hydrochloride, were selected from the drug-TF sub-network. Methotrexate and Dexamethasone are common in drug-TG and drug-TF sub-networks. In conclusion, this study proposed 16 drugs as potent candidates for NSCLC treatment through analyzing gene co-expression, TF–TG, and drug–gene interaction networks.en_US
dc.identifier.citationMotieGhader H, Tabrizi-Nezhadi P, Deldar Abad Paskeh M, Baradaran B, Mokhtarzadeh A, Hashemi M, Lanjanian H, Jazayeri SM, Maleki M, Khodadadi E, Nematzadeh S, Kiani F, Maghsoudloo M, Masoudi-Nejad A. Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis. Sci Rep. 2022 Jun 8;12(1):9417. doi: 10.1038/s41598-022-13719-8. PMID: 35676421; PMCID: PMC9177601.en_US
dc.identifier.doi10.1038/s41598-022-13719-8en_US
dc.identifier.issn2045-2322en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85131645660en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://doi.org/10.1038/s41598-022-13719-8
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2913
dc.identifier.volume12en_US
dc.identifier.wosWOS:000809083500075en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorLanjanian, Hossein
dc.institutionauthorKiani, Farzad
dc.language.isoenen_US
dc.publisherNatureen_US
dc.relation.ispartofScientific Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleDrug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
s41598-022-13719-8.pdf
Boyut:
2.57 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Moleküler Biyoloji ve Genetik Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu